Aims/hypothesis
Hyperglycaemia, one of the main features of diabetes, results in non-enzymatic glycation of plasma proteins, including apolipoprotein
A-I (apoA-I), the most abundant apolipoprotein in HDL. The aim of this study was to determine how glycation affects the structure
of apoA-I and its ability to activate lecithin:cholesterol acyltransferase (LCAT), a key enzyme in reverse cholesterol transport.
Materials and methods
Discoidal reconstituted HDL (rHDL) containing phosphatidylcholine and apoA-I ([A-I]rHDL) were prepared by the cholate dialysis
method and glycated by incubation with methylglyoxal. Glycation of apoA-I was quantified as the reduction in detectable arginine,
lysine and tryptophan residues. Methylglyoxal-AGE adduct formation in apoA-I was assessed by immunoblotting. (A-I)rHDL size
and surface charge were determined by non-denaturing gradient gel electrophoresis and agarose gel electrophoresis, respectively.
The kinetics of the LCAT reaction was investigated by incubating varying concentrations of discoidal (A-I)rHDL with a constant
amount of purified enzyme. The conformation of apoA-I was assessed by surface plasmon resonance.
Results
Methylglyoxal-mediated modifications of the arginine, lysine and tryptophan residues in lipid-free and lipid-associated apoA-I
were time- and concentration-dependent. These modifications altered the conformation of apoA-I in regions critical for LCAT
activation and lipid binding. They also decreased (A-I)rHDL size and surface charge. The rate of LCAT-mediated cholesterol
esterification in (A-I)rHDL varied according to the level of apoA-I glycation and progressively decreased as the extent of
apoA-I glycation increased.
Conclusions/interpretation
It is concluded that glycation of apoA-I may adversely affect reverse cholesterol transport in subjects with diabetes.
Keywords Apolipoprotein A-I - Diabetes - High-density lipoproteins - Lecithin:cholesterol acyltransferase - Non-enzymatic glycation